Overview

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to allow RC88 treatment of patients with advanced solid tumours to assess the safety and tolerability of clinical pharmacology studies
Phase:
Phase 1
Details
Lead Sponsor:
RemeGen Co., Ltd.